10388. Aflibercept

Nomenclature

CAS number: 862111-32-8
Vascular endothelial growth factor receptor type VEGFR-1 (synthetic human immunoglobulin domain 2 fragment) fusion protein with vascular endothelial growth factor receptor type VEGFR-2 (synthetic human immunoglobulin domain 3 fragment) fusion protein with immunoglobulin G1 (synthetic Fc fragment), dimer; vascular endothelial growth factor trap; VEGF Trap; VEGF TrapR1R2; VEGF Trap-Eye.

Description and references

Antiangiogenic agent. Recombinant human decoy fusion protein comprised of domain 2 of VEGF receptor-1 (Flt-1) and domain 3 of VEGF receptor-2 (Flk-1) fused to the Fc region of human IgG1. Prepn: N. J. Papadopoulos et al., WO 0075319; T. J. Daly et al., US 7396664 (2000, 2008 both to Regeneron); J. Holash et al., Proc. Natl. Acad. Sci. USA 99, 11393 (2002) DOI PubMed. Effect on choroidal neovascularization: Y. Saishin et al., J. Cell. Physiol. 195, 241 (2003) DOI PubMed. Clinical evaluation in age-related macular degeneration: Q. D. Nguyen et al., Ophthalmology 113, 1522 (2006) DOI PubMed; in diabetic macular edema: D. V. Do et al., Br. J. Ophthalmol. 93, 144 (2009) DOI PubMed. Review of evaluation as tumor angiogenesis inhibitor: Q. S.-C. Chu, Expert Opin. Biol. Ther. 9, 263-271 (2009) DOI PubMed.

Therapeutic Category

In treatment of age-related macular degeneration.

Keywords

Macular Degeneration Treatment